Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* HCV treatment-naive (HCV genotype 1, 2, 3 or 6), defined as no prior exposure to any interferon (IFN), RBV, or other approved or experimental HCV-specific direct-acting antiviral agent, or HCV treatment-experienced (HCV genotype 1, 2, 3, or 6 only) with medical records that include sufficient detail of prior treatment with IFN to allow for categorization of prior response as either IFN Intolerant, non-responder, or experiences viral breakthrough or relapse~* HCV infection documented by anti-HCV antibody test, genotyping test, or liver biopsy~Key Exclusion Criteria:~* Current or prior history of any clinically-significant illness (other than HCV)~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non-HCV etiology~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir+RBV+PEG 12 weeks (Type: EXPERIMENTAL): Participants with genotype 1 or 6 will receive sofosbuvir+RBV+Peg-IFNα-2a for 12 weeks.
- Sofosbuvir+RBV 12 weeks (Type: EXPERIMENTAL): Participants with genotype 1, 2 or 6 will receive sofosbuvir+RBV for 12 weeks.
- Sofosbuvir+RBV 16 weeks (Type: EXPERIMENTAL): Participants with genotype 1, 6 will receive sofosbuvir+RBV for 16 weeks.
- Sofosbuvir+RBV 24 Weeks (Type: EXPERIMENTAL): Participants with genotype 1, 3, or 6 will receive sofosbuvir+RBV for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).